Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker KRYS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jul 21, 2026 | A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease NCT07717346 · Hailey Hailey Disease, Skin Diseases KB111 | KRYS Krystal Biotech, Inc. | Early phase 1 | Recruiting | 7 | Nov 2026 | Registry ↗ |
| May 7, 2026 | A Study Assessing KB407 for the Treatment of Cystic Fibrosis NCT05504837 · Cystic Fibrosis KB407 (Nebulization) | KRYS Krystal Biotech, Inc. | Phase 1 | Recruiting | 20 | Dec 2026 | Registry ↗ |
| Mar 12, 2026 | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa NCT07016750 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermo… KB803, Placebo | KRYS Krystal Biotech, Inc. | Phase 3 | Recruiting | 16 | Dec 2026 | Registry ↗ |
| Feb 27, 2026 | A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis NCT06999733 · Neurotrophic Keratitis KB801, Placebo | KRYS Krystal Biotech, Inc. | Phase 1/2 | Recruiting | 60 | Dec 2026 | Registry ↗ |
| Oct 24, 2025 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326 · Lung Cancer, Non-small Cell, Lung Cancer Metastatic KB707, Pembrolizumab (KEYTRUDA®) | KRYS Krystal Biotech, Inc. | Phase 1/2 | Recruiting | 250 | Feb 2027 | Registry ↗ |
| Jul 22, 2025 | A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency NCT06049082 · Alpha 1-Antitrypsin Deficiency KB408 (Nebulization) | KRYS Krystal Biotech, Inc. | Phase 1 | Recruiting | 15 | Dec 2025 | Registry ↗ |
| Jul 2, 2025 | A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB) NCT06563414 · Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dy… | KRYS Krystal Biotech, Inc. | — | Recruiting | 40 | Dec 2025 | Registry ↗ |
| May 18, 2025 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497 · Cancer, Melanoma Stage III KB707, Opdualag | KRYS Krystal Biotech, Inc. | Phase 1/2 | Recruiting | 240 | Jul 2027 | Registry ↗ |
| May 13, 2025 | A Study Assessing KB304 for the Treatment of Wrinkles in Women NCT06724900 · Wrinkles in Decolletage, Pigmentation KB304, 0.9% Normal Saline (NS) | KRYS Krystal Biotech, Inc. | Phase 1/2 | Active, not recruiting | 19 | Jul 2025 | Registry ↗ |
| May 13, 2025 | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type I… NCT04540900 · Skin Roughness, Wrinkle KB301, Placebo | KRYS Krystal Biotech, Inc. | Phase 1 | Active, not recruiting | 85 | Oct 16, 2024 | Registry ↗ |
| Apr 9, 2024 | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa NCT04917874 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermo… Open Label Topical Beremagene Geperpavec (B-VEC) | KRYS Krystal Biotech, Inc. | Phase 3 | Completed | 47 | Jul 31, 2023 | Registry ↗ |
| Aug 14, 2023 | A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis NCT05095246 · Cystic Fibrosis KB407 (Nebulization) | KRYS Krystal Biotech, Inc. | Phase 1 | Withdrawn | 0 | Jul 1, 2024 | Registry ↗ |
| Feb 23, 2023 | Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) NCT05735158 · Autosomal Recessive Ichthyosis KB105, Placebo | KRYS Krystal Biotech, Inc. | Phase 2 | Unknown | 15 | Mar 2024 | Registry ↗ |
| Feb 17, 2023 | Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB NCT04491604 · Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epid… Topical Beremagene Geperpavec, Placebo | KRYS Krystal Biotech, Inc. | Phase 3 | Completed | 31 | Oct 29, 2021 | Registry ↗ |
| Jan 31, 2023 | A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients NCT03536143 · Dystrophic Epidermolysis Bullosa Topical beremagene geperpavec, Placebo gel | KRYS Krystal Biotech, Inc. | Phase 1/2 | Completed | 12 | Nov 1, 2019 | Registry ↗ |
| Sep 17, 2021 | The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) NCT04214002 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermo… | KRYS Krystal Biotech, Inc. | — | Withdrawn | 0 | Feb 24, 2020 | Registry ↗ |
| Sep 13, 2021 | Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichth… NCT04047732 · TGM-1 Related Autosomal Recessive Congenital Ichthyosis KB105 | KRYS Krystal Biotech, Inc. | Phase 1/2 | Unknown | 6 | Oct 2022 | Registry ↗ |
| Jun 8, 2021 | Long-Term Follow-up Protocol NCT04917887 · Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epid… | KRYS Krystal Biotech, Inc. | — | Recruiting | 50 | May 25, 2028 | Registry ↗ |
18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:25 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances